2018 Sickle Cell Disease Or Sickle Cell Anemia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Sickle Cell Disease Or Sickle Cell Anemia Market
Sickle cell disease (SCD) is a group of diseases occurring due to abnormal hemoglobin, which deforms the RBCs into sickle shape, which restricts them from free flow of blood, resulting in extreme pain and ultimately can lead to death. It is a common genetic disorder, which affects around 5 million population worldwide. It is caused by a single mutation in the beta-globin gene. African and Asian population is more susceptible to the disease. In the US alone, Sickle cell disease market value is estimated to be around $1.2 billion.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Sickle Cell Disease Or Sickle Cell Anemia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Sickle Cell Disease Or Sickle Cell Anemia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Sickle Cell Disease Or Sickle Cell Anemia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Sickle Cell Disease Or Sickle Cell Anemia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Sickle Cell Disease Or Sickle Cell Anemia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Sickle Cell Disease Or Sickle Cell Anemia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 SICKLE CELL DISEASE OR SICKLE CELL ANEMIA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Sickle Cell Disease Or Sickle Cell Anemia Pipeline Snapshot
2.3 Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Phase
2.4 Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Company
2.5 Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Mechanism of Action
3 SICKLE CELL DISEASE OR SICKLE CELL ANEMIA- COMPANY WISE PIPELINE ANALYSIS
Acceleron Pharma Inc
Addmedica SAS
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
AstraZeneca Plc
Bicycle Therapeutics Limited.
bluebird bio, Inc.
Bristol-Myers Squibb Co
Calimmune Inc
Cancer Therapeutics CRC Pty Ltd
CRISPR Therapeutics AG
CSL Ltd
Daiichi Sankyo Co Ltd
DeuteRx LLC
Editas Medicine Inc
Epidestiny Inc
Epizyme, Inc.
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Genethon SA
Global Blood Therapeutics Inc
GlycoMimetics, Inc.
Hillhurst Biopharmaceuticals Inc
Imara Inc
Incyte Corp
Intellia Therapeutics, Inc
Invenux LLC
Ironwood Pharmaceuticals Inc
La Jolla Pharmaceutical Company
Merganser Biotech Inc
Modus Therapeutics AB
Molecules For Health Inc
Morphogenesis Inc
NKT Therapeutics Inc
Novartis AG
NuvOx Pharma LLC
Orphagen Pharmaceuticals Inc
Oryzon Genomics S.A.
PHD Biosciences HQ
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Regenacy Pharmaceuticals, LLC
ReveraGen BioPharma Inc
Sancilio & Company Inc
Sangamo Therapeutics Inc
Syros Pharmaceuticals, Inc.
Vanguard Therapeutics Inc
4 SICKLE CELL DISEASE OR SICKLE CELL ANEMIA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN SICKLE CELL DISEASE OR SICKLE CELL ANEMIA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 SICKLE CELL DISEASE OR SICKLE CELL ANEMIA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Sickle Cell Disease Or Sickle Cell Anemia Pipeline Snapshot
2.3 Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Phase
2.4 Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Company
2.5 Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Mechanism of Action
3 SICKLE CELL DISEASE OR SICKLE CELL ANEMIA- COMPANY WISE PIPELINE ANALYSIS
Acceleron Pharma Inc
Addmedica SAS
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
AstraZeneca Plc
Bicycle Therapeutics Limited.
bluebird bio, Inc.
Bristol-Myers Squibb Co
Calimmune Inc
Cancer Therapeutics CRC Pty Ltd
CRISPR Therapeutics AG
CSL Ltd
Daiichi Sankyo Co Ltd
DeuteRx LLC
Editas Medicine Inc
Epidestiny Inc
Epizyme, Inc.
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Genethon SA
Global Blood Therapeutics Inc
GlycoMimetics, Inc.
Hillhurst Biopharmaceuticals Inc
Imara Inc
Incyte Corp
Intellia Therapeutics, Inc
Invenux LLC
Ironwood Pharmaceuticals Inc
La Jolla Pharmaceutical Company
Merganser Biotech Inc
Modus Therapeutics AB
Molecules For Health Inc
Morphogenesis Inc
NKT Therapeutics Inc
Novartis AG
NuvOx Pharma LLC
Orphagen Pharmaceuticals Inc
Oryzon Genomics S.A.
PHD Biosciences HQ
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Regenacy Pharmaceuticals, LLC
ReveraGen BioPharma Inc
Sancilio & Company Inc
Sangamo Therapeutics Inc
Syros Pharmaceuticals, Inc.
Vanguard Therapeutics Inc
4 SICKLE CELL DISEASE OR SICKLE CELL ANEMIA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN SICKLE CELL DISEASE OR SICKLE CELL ANEMIA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Phase, H2- 2018
Figure 2: Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Phase, H2- 2018
Figure 2: Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Phase, H2- 2018
Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Companies, H2- 2018
Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Mechanism of Action, H2- 2018
Table 1: Acceleron Pharma Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 2: Addmedica SAS Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 3: Angiocrine Bioscience Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 4: Annexin Pharmaceuticals AB Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 5: ArQule Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 6: AstraZeneca Plc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 7: Bicycle Therapeutics Limited. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 8: bluebird bio, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 9: Bristol-Myers Squibb Co Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 10: Calimmune Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 11: Cancer Therapeutics CRC Pty Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 12: CRISPR Therapeutics AG Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 13: CSL Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 14: Daiichi Sankyo Co Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 15: DeuteRx LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 16: Editas Medicine Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 17: Epidestiny Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 18: Epizyme, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 19: Errant Gene Therapeutics LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 20: Gamida Cell Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 21: Genethon SA Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 22: Global Blood Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 23: GlycoMimetics, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 24: Hillhurst Biopharmaceuticals Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 25: Imara Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 26: Incyte Corp Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 27: Intellia Therapeutics, Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 28: Invenux LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 29: Ironwood Pharmaceuticals Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 30: La Jolla Pharmaceutical Company Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 31: Merganser Biotech Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 32: Modus Therapeutics AB Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 33: Molecules For Health Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 34: Morphogenesis Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 35: NKT Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 36: Novartis AG Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 37: NuvOx Pharma LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 38: Orphagen Pharmaceuticals Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 39: Oryzon Genomics S.A. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 40: PHD Biosciences HQ Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 41: Phoenicia Biosciences Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 42: Prolong Pharmaceuticals LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 43: Regenacy Pharmaceuticals, LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 44: ReveraGen BioPharma Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 45: Sancilio & Company Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 46: Sangamo Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 47: Syros Pharmaceuticals, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 48: Vanguard Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Phase, H2- 2018
Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Companies, H2- 2018
Sickle Cell Disease Or Sickle Cell Anemia Pipeline by Mechanism of Action, H2- 2018
Table 1: Acceleron Pharma Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 2: Addmedica SAS Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 3: Angiocrine Bioscience Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 4: Annexin Pharmaceuticals AB Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 5: ArQule Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 6: AstraZeneca Plc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 7: Bicycle Therapeutics Limited. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 8: bluebird bio, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 9: Bristol-Myers Squibb Co Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 10: Calimmune Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 11: Cancer Therapeutics CRC Pty Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 12: CRISPR Therapeutics AG Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 13: CSL Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 14: Daiichi Sankyo Co Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 15: DeuteRx LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 16: Editas Medicine Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 17: Epidestiny Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 18: Epizyme, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 19: Errant Gene Therapeutics LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 20: Gamida Cell Ltd Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 21: Genethon SA Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 22: Global Blood Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 23: GlycoMimetics, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 24: Hillhurst Biopharmaceuticals Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 25: Imara Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 26: Incyte Corp Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 27: Intellia Therapeutics, Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 28: Invenux LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 29: Ironwood Pharmaceuticals Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 30: La Jolla Pharmaceutical Company Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 31: Merganser Biotech Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 32: Modus Therapeutics AB Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 33: Molecules For Health Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 34: Morphogenesis Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 35: NKT Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 36: Novartis AG Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 37: NuvOx Pharma LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 38: Orphagen Pharmaceuticals Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 39: Oryzon Genomics S.A. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 40: PHD Biosciences HQ Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 41: Phoenicia Biosciences Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 42: Prolong Pharmaceuticals LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 43: Regenacy Pharmaceuticals, LLC Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 44: ReveraGen BioPharma Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 45: Sancilio & Company Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 46: Sangamo Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 47: Syros Pharmaceuticals, Inc. Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
Table 48: Vanguard Therapeutics Inc Sickle Cell Disease Or Sickle Cell Anemia Pipeline Drugs, H2- 2018
